DrugPatentWatch Database Preview
Drugs in Development Information for IMO-2125
» See Plans and Pricing
What is the drug development status for IMO-2125?
IMO-2125 is an investigational drug.
There have been 18 clinical trials for IMO-2125.
The most recent clinical trial was a Phase 2 trial, which was initiated on February 28th 2018.
The most common disease conditions in clinical trials are Melanoma, Hepatitis C, and Psoriasis. The leading clinical trial sponsors are Idera Pharmaceuticals, Inc., EMD Serono, and A.J.M. van den Eertwegh.
There are three US patents protecting this investigational drug and nine international patents.
Summary for IMO-2125
| US Patents | 3 |
| International Patents | 9 |
| US Patent Applications | 0 |
| WIPO Patent Applications | 0 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 2 (2018-02-28) |
| Vendors | 0 |
Recent Clinical Trials for IMO-2125
| Title | Sponsor | Phase |
|---|---|---|
| A Randomized Controlled Phase II Trial With Intradermal IMO-2125 in Pathological Tumor Stage (p) T3-4 cN0M0 Melanoma | Idera Pharmaceuticals, Inc. | Phase 2 |
| A Randomized Controlled Phase II Trial With Intradermal IMO-2125 in Pathological Tumor Stage (p) T3-4 cN0M0 Melanoma | A.J.M. van den Eertwegh | Phase 2 |
| Study of Tilsotolimod in Combination With Nivolumab and Ipilimumab for the Treatment of Solid Tumors (ILLUMINATE-206) | Idera Pharmaceuticals, Inc. | Phase 2 |
Clinical Trial Summary for IMO-2125
Top disease conditions for IMO-2125
Top clinical trial sponsors for IMO-2125
US Patents for IMO-2125
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| IMO-2125 | Start Trial | Immune modulation with TLR9 agonists for cancer treatment | IDERA PHARMACEUTICALS, INC. (Exton, PA) | Start Trial |
| IMO-2125 | Start Trial | Immune modulation with TLR9 agonists for cancer treatment | IDERA PHARMACEUTICALS, INC. (Exton, PA) | Start Trial |
| IMO-2125 | Start Trial | Immune modulation with TLR9 agonists for cancer treatment | IDERA PHARMACEUTICALS, INC. (Exton, PA) | Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for IMO-2125
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| IMO-2125 | Australia | AU2017325981 | 2036-09-15 | Start Trial |
| IMO-2125 | Canada | CA3036978 | 2036-09-15 | Start Trial |
| IMO-2125 | China | CN110114057 | 2036-09-15 | Start Trial |
| IMO-2125 | European Patent Office | EP3512499 | 2036-09-15 | Start Trial |
| IMO-2125 | Israel | IL265370 | 2036-09-15 | Start Trial |
| IMO-2125 | Japan | JP2019529415 | 2036-09-15 | Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
